Feb '17

12th Congress of European Crohn’s and Colitis Organisation (ECCO) – Inflammatory Bowel Diseases 2017

P369 Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers
Download Abstract

DOP077 Immunomodulatory Effects of Etrasimod APD334 an Oral Potent
Download Abstract

DOP078 Pharmacology and Safety of Etrasimod APD334 an Oral Potent
Download Abstract

Dec '16

Advances in Inflammatory Bowel Diseases (AIBD) Meeting

Safety, Pharmacokinetics and Pharmacodynamics of Etrasimod (APD334), an Oral, Selective S1P Receptor Modulator, after Single Dose Escalation in Healthy Volunteers
View Poster

Etrasimod (APD334), a Potent, Selective, Oral S1P Receptor Modulator With Preclinical Autoimmune Disease-modifying Activity Exhibits Favorable PK/PD Properties in Healthy Volunteers
View Poster

Preclinical Safety Assessment of Etrasimod (APD334), an Oral Sphingosine-1-Phosphate Receptor (S1P) Modulator with a Favorable Profile
View Poster

The Sphingosine-1-Phosphate Receptor (S1P) Modulator Etrasimod (APD334) Demonstrates Limited Effects on Heart Rate in Preclinical Testing
View Poster

Oct '16

United European Gastroenterology Week (UEGW) Meeting

Abstract 5531 – Receptor Profile and Efficacy of Etrasimod (APD334), an Oral, Next-Generation Sphingosine-1-Phosphate Receptor Modulator in Development for Ulcerative Colitis
View Abstract


Jan '17

Journal of Medicinal Chemistry

Discovery of 2‑(((1r,4r)‑4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
View PDF

Nov '16

American Heart Association (AHA) Meeting

APD811, a Novel and Highly Selective Non-prostanoid IP Receptor Agonist in Smooth Muscle Cells From Patients With Pulmonary Hypertension
View Poster